One drug, two different questions
A 2020 randomized, double-blind trial assigned 286 people with cardiovascular disease and elevated Lp(a) to an antisense drug or placebo. Its primary endpoint was the change in Lp(a) after six months.
The largest mean reduction was 80%, compared with 6% on placebo. Those are changes in blood concentrations, not reductions in heart attacks. Injection-site reactions were the most common adverse events; this small trial cannot establish long-term safety. Akcea Therapeutics funded it.
Our reading: a trial can establish that a drug changes its intended marker without establishing that patients live longer or avoid cardiovascular events. The endpoint determines which question the result answers.
This revisits the original 2020 journal abstract; it is not a journal report of the recent outcomes trial. In a September 4, 2026 company announcement, Novartis reported that the later pelacarsen Lp(a)HORIZON trial missed its primary cardiovascular endpoint. That topline announcement supplies no hazard ratio or confidence interval. It cannot tell us the size or precision of the effect, or settle the question for every Lp(a)-lowering drug.
Source: New England Journal of Medicine (2020). Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Journal: https://doi.org/10.1056/NEJMoa1905239
PubMed: https://pubmed.ncbi.nlm.nih.gov/31893580/
Company announcement (not peer-reviewed): https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd
AI-assisted analysis. Educational, not medical advice.
Comments